GGrantIndex
← Leaderboards

Charles T Roberts

Oregon Health & Science University

$5,489,068
Attributed
$12,509,264
Total exposure
16
Grants
15
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3M · FY200825
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,509,264 · 16

By mechanism

R01$9,559,912 · 2
P50$1,800,969 · 2
R24$502,127 · 1
P51$493,189 · 10
U54$153,067 · 1

Top collaborators

Most similar at Oregon Health & Science University

Same institution · by research overlap

Others in their field

Top investigators on “Nonhuman Primate

Research focus

Nonhuman PrimateObesityInsulin ResistanceMetabolicAdipose TissueTissuesExhibitsMetabolic DiseasesChronicNon-Insulin-Dependent Diabetes MellitusFunctional DisorderMacacaSamplingIsletAffectEndocrineLipid MetabolismPre-Clinical ModelConsumptionInsulinMacaca MulattaBlood Glucose RegulationMaleMonitor

Grant awards (30)

Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$997,077
R01 · FY2025 · DK · contact PI
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$951,400
R01 · FY2024 · DK · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$1,286,550
R01 · FY2023 · DK · contact PI
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$994,162
R01 · FY2023 · DK · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$693,828
R01 · FY2023 · DK · contact PI
Post-acute metabolic sequelae of SARS-CoV-2 infection in nonhuman primates$1,286,550
R01 · FY2022 · DK · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$824,832
R01 · FY2022 · DK · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$841,023
R01 · FY2021 · DK · contact PI
Metabolic and Adipose Responses to Hyperandrogenemia and Diet$247,445
P50 · FY2021 · HD · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$827,788
R01 · FY2020 · DK · contact PI
Metabolic and Adipose Responses to Hyperandrogenemia and Diet$292,663
P50 · FY2020 · HD · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$856,702
R01 · FY2019 · DK · contact PI
Metabolic and Adipose Responses to Hyperandrogenemia and Diet$318,185
P50 · FY2019 · HD · contact PI
Metabolic and Adipose Responses to Hyperandrogenemia and Diet$283,740
P50 · FY2018 · HD · contact PI
Project 3: Effects of Androgen and Diet on Adipose Function$167,938
P50 · FY2017 · HD · contact PI
Project 3: Effects of Androgen and Diet on Adipose Function$153,067
P50 · FY2016 · HD · contact PI
Project 3: Effects of Androgen and Diet on Adipose Function$167,937
P50 · FY2015 · HD · contact PI
Project 3: Effects of Androgen and Diet on Adipose Function$169,994
P50 · FY2014 · HD · contact PI
Project 3: Effects of Androgen and Diet on Adipose Function$153,067
U54 · FY2013 · HD · contact PI
Molecular mechanisms underlying NHP pancreatic beta cell failure, and recovery$502,127
R24 · FY2011 · DK
MOLECULAR MECHANISMS OF HUMAN AND MURINE BETA CELL PROLIFERATION & REGENERATION$43,647
P51 · FY2011 · RR · contact PI
YR 50 PROJ- ROBERTS PRIMATE ISLET$43,647
P51 · FY2011 · RR · contact PI
HERSTATIN: A NOVEL CANCER THERAPEUTIC$43,647
P51 · FY2011 · RR · contact PI
ALOGLIPTIN EFFECTS ON PANCREATIC ISLET FUNCTION$76,080
P51 · FY2010 · RR · contact PI
HERSTATIN: A NOVEL CANCER THERAPEUTIC$57,095
P51 · FY2010 · RR · contact PI
YR 50 PROJ- ROBERTS PRIMATE ISLET$47,603
P51 · FY2010 · RR · contact PI
A NOVEL MECHANISM OF ANDROGEN RECEPTOR ACTION$80,343
P51 · FY2009 · RR · contact PI
A PHASE-I/II STUDY OF IMC-A12 IN CHILDREN WITH RELAPSED/ REFACTORY SOLID TUMORS"$34,471
P51 · FY2009 · RR · contact PI
A NOVEL MECHANISM OF ANDROGEN RECEPTOR ACTION$55,512
P51 · FY2008 · RR · contact PI
REGULATION OF VESSEL REGRESSION IN ISCHEMIC RETINOPATHY$11,144
P51 · FY2008 · RR · contact PI